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Summary
Background Patients with squamous cell skin cancer (SCC) have an excellent prog-
nosis but second primary cancers (SPCs) weaken survival prospects. Family his-
tory is a known risk factor for cancer but whether it is a risk factor for SPC in
patients with SCC is not known.
Objectives To quantify the risk of family history on SPCs in patients with SCC and
estimate survival probabilities of patients with SPCs depending on family history.
Methods With 13 945 histologically verified SCCs, relative risks (RRs) were esti-
mated for family history using a generalized regression model. For survival analy-
sis, hazard ratios (HRs) were assessed using a multivariable Cox proportional-
hazards model.
Results Family history of invasive SCC increased risk of second invasive SCC [RR =
4292, 95% confidence interval (CI) 3369–5032] compared with risk without
family history (RR 1912, 95% CI 1788–2108). Family history of any nonskin
cancer in invasive SCC increased risk of the same cancers to be diagnosed as SPC
(RRFH = 148, 95% CI 135–161 vs. RRno FH = 140, 95% CI 132–148); sig-
nificant increases were observed for seven different nonskin cancers. Most results
were replicated for in situ SCC. SPC was deleterious for survival irrespective of
family history; HR for patients with SPC was 428 (95% CI 383–472) vs. those
without SPC (104).
Conclusions Family history of nonskin cancer was associated with approximately a
doubling of risk for SPCs in patients with SCC. SPC increases the death rate in
patients with SCC 3–4 times, irrespective of family history. Taking family history
into account at SCC diagnosis may help prevention or early detection of SPCs.
What’s already known about this topic?
• Second primary cancers (SPCs) are frequently diagnosed in patients with invasive
and in situ squamous cell carcinoma (SCC); some epidemiological studies suggest a
link to immune dysfunction.
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• Family history of cancer is a risk factor for practically all first primary cancers but
whether it also influences risk of SPCs in patients with SCC is not known.
• The possible influence of family history on survival in patients with SCC remains
to be established.
What does this study add?
• Of 88 million individuals, 2743 (20%) of 13 945 patients with invasive SCC
developed SPC.
• Family history of a cancer increased the risk of that cancer being diagnosed as SPC
approximately twofold on top of the overall elevated risk of SPC; diagnosis of SPC
increased death rate approximately 3–4 times vs. patients with SCC without SPC.
• Family history influenced survival indirectly by increasing the number of SPCs.
Squamous cell skin carcinoma (SCC) and its precursor, in situ
SCC (Bowen disease), are common cancers with generally
increasing incidence rates in fair-skinned populations.1–3 The
10-year absolute survival in SCC was 73% according to a large
German study; survival rate was best for women and younger
individuals.4 Risk factors for skin SCC include cumulative
exposure to ultraviolet radiation, sun-sensitive skin, immuno-
suppression, and exposures to arsenic, glucocorticoids and
polycyclic hydrocarbons.3 The importance of the first two risk
factors is underlined by the fact that SCC of the skin is over-
whelmingly diagnosed on the face.1,4
Family history is an often forgotten risk factor, although
the familial risk for SCC of about 20 between first-degree
relatives is approximately as high as among other common
cancers.5–7 However, familial risk of SCC may increase up
to 15-fold when several family members are affected; the
risk can even be noted among patients diagnosed beyond
age 90 years.8,9 Invasive and in situ SCCs share familial risks
between them.6 SCC is additionally associated with some
other cancers in families, most notably with cutaneous mel-
anoma.10 Counting any cancers among the first-degree rela-
tives of patients with SCC, 7% have SCC and 54% have any
other cancer.11 SCC is a manifestation of some very rare
cancer syndromes, including xeroderma pigmentosum, Fan-
coni anaemia, and Bloom and Werner syndromes.3,12 Gen-
ome-wide association studies on SCC have identified some
20 low-risk loci, many of which function in pigmentation,
immune regulation or oncogenic pathways.3,13,14 As survival
in SCC is good, patients are often at risk of developing sec-
ond primary cancers (SPCs). A systematic review summa-
rized results from 10 studies reporting on SPCs after skin
SCC and found significant increases for salivary gland, lip,
mouth and pharynx, and lung cancer, and for melanoma
and non-Hodgkin lymphoma.15 In our previous study, we
found that the risks for SPCs were quite similar between
invasive and in situ SCC.16
The aim of the present study was to estimate the influence
of family history on the risk of SPCs in patients with primary
invasive or in situ SCC. We also hypothesized that family his-
tory of cancer X increases the risk for cancer X to be an SPC,
as has been observed for some other cancers.17–21 We addi-
tionally tested if family history of skin cancer increases risk of
second SCC after nonskin cancer. Some recent results on pros-
tate, breast and ovarian cancers suggest that the cause of death
in patients with SPC is often the SPC;18,19,22 therefore, we
assessed survival in patients with SCC who were diagnosed
with SPC and whether survival is influenced by family history
of SPC.
The study was approved by the Ethical Committee of Lund
University, Sweden, without requirement for informed con-
sent, and was conducted in accordance with the tenets of the
Declaration of Helsinki. The project database is located at the
Center for Primary Health Care Research in Malm€o, Sweden.
Before the database construction, it was advertised in major
newspapers to offer people an option for withdrawal.
Patients and methods
Study population
Data for the study were obtained from the Swedish Family-
Cancer Database, which includes information on the residents
of Sweden organized in families and linked to the Swedish
Cancer Registry, which was started in 1958.23 The Cancer
Registry records cancers according to the International Classifi-
cation of Diseases 7th revision (ICD-7) and later revisions. By
the end of 2015 more than two million cancers were recorded
among 161 million living and dead individuals, with 88 mil-
lion individuals belonging to the 0–83-year-old offspring gen-
eration (born after 1931) for which relative risks (RRs) were
calculated. Everyone in Sweden is assigned a unique identifier
at birth. The Multigeneration Register uses these identifiers to
link newborns to their parents and in the Family-Cancer Data-
base these data are used to assemble families. In the present
analysis two generations were used: offspring with siblings
and parents.
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Data collection
We followed newly diagnosed patients with SCC from 1 Jan-
uary 1981 to 31 December 2015 for diagnosis of any of 28
different SPCs; only invasive SPCs were considered, except that
in situ SCC was also considered. Family history was attributed
in two separate designs, firstly as nonskin cancer family his-
tory, if at least one relative was diagnosed with the same non-
skin SPCs as the patient; and secondly as invasive skin cancer
family history, when at least one relative was diagnosed with
SCC. Family history was recorded from the beginning of can-
cer registration in Sweden from the year 1958 onwards. Fol-
low-up was initiated in 1981, year of birth, diagnosis of first
cancer or immigration, whichever occurred latest, and was
terminated at diagnosis of SPC, emigration, death, or 31
December 2015 (when the oldest individuals reached age 83
years), whichever occurred earliest. If in situ SCC and SCC were
diagnosed in a person at the same time, SCC was given prece-
dence.
Statistical analysis
Incidence rates were computed for each stratum over vec-
tored categories of sex, age group, calendar period, residen-
tial area and socioeconomic status. Familial and nonfamilial
RRs of SPC were estimated by comparing risk (incidence
rate) of SPC among patients with SCC, with or without
prior family history, against risk of that cancer in the gen-
eral population. Waiting time distribution with Poisson
assumption was employed to estimate RRs and correspond-
ing confidence intervals (CIs) at a 5% level of significance.
RRs were calculated for the offspring generation. A general-
ized linear multivariate model was used with regressor vari-
ables including age group, sex, calendar period, residential
area and socioeconomic status as adjustment for potential
confounding.
For the sensitivity analysis, a test of trend was constructed
for comparing statistically significant difference between two
risk strata. This was achieved by constructing Pearson v2 statis-
tics between the groups, taking two separate bootstrapped
samples with 100 000 resamples. All tests were considered to
be statistically significant at P < 005, although significance of
RRs was additionally indicated for P < 001 and P < 0001.
Overall survival was modelled with multivariable Cox
regression analysis, subject to conformity to the proportional-
hazards assumption. The model was adjusted for sex, age
group, residential area and socioeconomic status. Observations
were censored for diagnosis of cancer other than SCC. Separate
analyses were performed for invasive and in situ SCC, consider-
ing diagnosis of a nonskin SPC and presence of family history
of any cancer. Assessment of survival probabilities and hazard
ratios (HRs) of patients with SCC was performed for patients
without SPC and no family history as the baseline hazard. All
statistical analyses were implemented in R version 3424 and
SAS V94 (SAS Institute Inc., Cary, NC, U.S.A.).
Results
Individuals belonging to the offspring generation were fol-
lowed from 1981 to 2015, and 13 945 invasive SCCs and
15 797 in situ skin cancers were recorded. Among the people
with invasive SCCs, there were 1325 nonskin SPCs [median
(interquartile range) follow-up in 3 years (1–7)], 1418 sec-
ond invasive SCCs [2 (0–6)] and 1232 second in situ SCCs [4
(1–8)]. Median age at diagnosis of first invasive SCC was 68
years (58–72). After first invasive SCC, median age at diagno-
sis of nonskin SPCs was 72 years (68–76); for second invasive
SCCs it was 69 years (67–72) and for second in situ SCCs, 72
years (69–77). In patients with in situ SCC, there were 1455
nonskin SPCs [5 (1–8)], 885 second invasive SCCs [1 (0–3)]
and 1226 second in situ SCCs [2 (1–5)]. Median age at diagno-
sis for first in situ SCC was 68 years (61–74), for nonskin SPCs
it was 72 years (69–76), for second invasive SCCs it was 69
years (68–72) and for second in situ SCCs it was 69 years (67–
73). Median follow-up times from a nonskin cancer as first
cancer to second invasive and in situ SCC were both 7 years.
Table 1 shows the influence of family history on the risk of
SPC in patients diagnosed with invasive and in situ SCC. When
invasive SCC was the first cancer, the RR of second invasive
SCC increased when there was a family history of invasive
SCC [RRno FH = 1912 (95% CI 1788–2108); RRFH of SCC =
4292 (95% CI 3369–5032)]. The RR for second in situ SCC
[RRno FH = 1692 (95% CI 1542–1883)] also increased if
there was a family history of invasive SCC [RRFH of SCC =
3216 (95% CI 2140–4179)]. A similar increase in RR was
noted for second invasive SCC after in situ SCC [RRno FH =
682 (95% CI 439–824) vs. RRFH of SCC = 1561 (95% CI
818–2059)]. Likewise, for second in situ SCC, the RR also
increased in the presence of family history [RRno FH = 1185
(95% CI 1029–1327) vs. RRFH of SCC = 2183 (95% CI
1741–2516)]. All RRs in Table 1 were significant at the
01% level and trend-test P-values were < 0001.
Table 2 shows risks for discordant (nonskin) SPC after SCC,
stratified over family history of the discordant cancer
(we abbreviate this as ‘SCC – cancer X, FH of cancer X’).
When the first cancer was invasive SCC (upper part of
Table 2), 11 SPCs had their risk increased given family history
of the SPC, as judged from the trend test. Overall risk for non-
skin SPC was increased [RRFH = 148 (95% CI 135–161) vs.
RRno FH = 140 (95% CI 132–148), significant at the 5%
level or lower]. Note that the overall risk considered only con-
cordant family histories: e.g. for second colorectal cancer a
family member was diagnosed with colorectal cancer. The RRs
for familial SPCs vs. RRs without family history were increased
approximately one-and-a-half-fold for colorectal cancer
[RRFH of colorectal = 226 (95% CI 118–435) vs. RRno FH
=134 (95% CI 115–157)] and non-Hodgkin lymphoma
(NHL), and twofold for prostate cancer, melanoma and leu-
kaemia. Increases greater than twofold were observed for
lung, bladder and pancreatic cancers. The trend test was sig-
nificant for all sets of comparisons except for the two
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haematological cancers. The lower part of Table 2 shows
results for SPCs following in situ SCC. SPCs were included only
when the trend test for family history was significant; these
included second colorectal, lung, breast and prostate cancers.
Table 3 shows RRs for second primary SCCs after nonskin
cancers under the influence of family history of SCC (cancer X
– SCC, FH of SCC). The upper part of Table 3 shows the
increased risks for SPCs, depending on family history, for
seven SPCs, including upper aerodigestive tract, colorectal,
breast and prostate cancers, melanoma, NHL and leukaemia.
RRs between SPCs, with and without family history, were
increased approximately twofold for most familial patients
with SCC. For all patients with nonskin cancer, an overall
increase was also noted [RRFH of SCC = 427 (95% CI 341–
533) vs. RRno FH = 210 (95% CI 201–219); P < 0001].
The lower part of Table 3 summarizes a similar analysis con-
ducted for in situ SCC. The trend test for family history of SCC
was statistically significant due to increased RRs in familial
second primary SCCs after colorectal, breast, endometrial and
prostate cancers, melanoma and leukaemia.
Figure 1 depicts Kaplan–Meier survival curves for patients
with SCCs grouped over SPCs with or without family history
of any concordant cancer; SCC was not included as SPC in sur-
vival analysis. Patients with SCC without SPC and/or family
history of cancer were considered as the reference group.
Under the assumption of independent proportional hazards,
HRs for patients with SPC were greatly increased, irrespective
of family history [HRSPC, any FH = 428 (95% CI 383–472),
P < 0001 vs. HRSPC, no FH = 365 (95% CI 306–428),
P < 0001]. Furthermore, family history had no influence on
Table 1 Risk of second primary skin cancers among patients with skin cancer stratified over family history of skin cancer
Number of first-degree relatives with cancer
Trend test
P-value
≥ 1 0
n RR (95% CI) n RR (95% CI)
First cancer: invasive skin cancer
Second cancer:
Invasive skin 143 4292 (3369–5032) 1275 1912 (1788–2108) < 0001
In situ skin 109 3216 (2140–4179) 1123 1692 (1542–1883) < 0001
First cancer: in situ skin cancer
Second cancer:
Invasive skin 83 1561 (818–2059) 802 682 (439–824) < 0001
In situ skin 207 2183 (1741–2516) 1019 1185 (1029–1327) < 0001
RR, Relative risk; CI, confidence interval. All RRs significant at P < 0001.
Table 2 Risk of second primary nonskin cancer after skin cancer stratified over family history of the nonskin cancer
Number of first-degree relatives with cancer
Trend test
P-value
≥ 1 0
n RR (95% CI) n RR (95% CI)
Second cancer after invasive skin cancer
Colorectum 9 226 (118–435)* 129 134 (115–157)** < 0001
Pancreas 3 2115 (682–6562)* 22 113 (079–162) 001
Lung 9 414 (215–796)** 108 146 (123–174)** < 0001
Breast 10 166 (090–309)* 133 142 (121–166)** 003
Prostate 35 215 (155–300)** 279 111 (099–123) < 0001
Bladder 4 558 (209–1487)** 53 154 (122–194)** 003
Melanoma 9 741 (385–1425)** 126 304 (259–357)** 004
Non–Hodgkin lymphoma 2 505 (126–2020)** 89 304 (250–371)** 013
Leukaemia 1 431 (061–3060) 49 214 (167–274)** 021
All (except skin) 99 148 (135–161)** 1226 140 (132–148)** 002
Second cancer after in situ skin cancer
Colorectum 8 194 (110–342)** 152 103 (090–118) 002
Lung 5 245 (123–491)** 99 100 (085–119) < 0001
Breast 16 201 (131–308)** 193 112 (098–127) < 0001
Prostate 33 205 (156–269)** 308 110 (100–121)* < 0001
All (except skin) 78 161 (150–173)** 1377 102 (097–110) < 0001
RR, Relative risk; CI, confidence interval. *P < 005, **P < 001.
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survival in patients without SPC [HRno SPC, no FH = 104 (95%
CI 091–126), P = 059]. However, detrimental effects of SPC
combined with family history was observed for patients with
in situ SCC [HRSPC, any FH = 615 (95% CI 528–719), P <
0001], while HRs for SPC with no or any family history were
both nominal and statistically insignificant (HRSPC, no FH =
102 and HRno SPC, any FH = 104).
Discussion
Our findings demonstrated that risks for second SCC after a
primary SCC are very high and not very different for invasive
(RR 1912) and in situ SCC (RR 1185), as previously
reported.16 We showed also that a concordant family history
was associated with almost twice the increased risk for SPC,
with 4292 for invasive and 2183 for in situ SCC. Familial
risks for concordant invasive and in situ SCCs are known to be
approximately 20 or somewhat higher.6,11 Thus we suggest,
as a novel hypothesis, that the results on familial SPC can be
rationalized by a multiplicative interaction between SPC (RR
approximately 20) and familial risk (RR approximately 2). We
further assessed whether multiplicative interactions may also
apply to discordant associations, as discussed below.
Previous studies have shown that family history may
increase the risk of some SPCs after Hodgkin lymphoma, mul-
tiple myeloma, prostate cancer and melanoma.17,20,21,25 We
showed here that family history of seven cancers was associ-
ated with an increased risk of their being diagnosed as SPCs
after invasive SCC, and for four SPCs the results were repli-
cated for the first in situ SCC (SCC – cancer X, FH of cancer X).
We observed that most familial risks for SPCs increased
the RRs about twofold over the RRs for SPC. As concordant
familial risks for most cancers are about twofold, the multi-
plicative interactions appear to describe the result quite satis-
factorily.11
We showed also that the risk for second primary SCC was
increased when there was a family history of SCC (cancer X –
SCC, FH of SCC). The first cancers were upper aerodigestive
tract, colorectal, breast and prostate cancers, melanoma, NHL
and leukaemia, and of these all but NHL were replicated for
second in situ SCC. The increase in RR was also about twofold.
These two sets of results can be rationalized by hypothesizing
that a family history of nonskin cancer will manifest itself irre-
spective of first SCC, and family history of SCC will manifest
itself irrespective of first nonskin cancers.
The qualification to the above statement is that the associ-
ated nonskin cancers appeared to be a defined set that consis-
tently included colorectal and prostate cancers, melanoma and
leukaemia. Breast cancer, including other hormone related
female cancers, upper aerodigestive tract cancer and NHL were
also often present as significant partners. One obvious com-
mon denominator for these nonskin cancers is that they were
common, and thus least limited by statistical power to mani-
fest the familial risk. Some of these cancers also share risk fac-
tors with skin cancer, including melanoma (ultraviolet
radiation), and NHL, leukaemia and upper aerodigestive tract
cancer (infections and immune deficiency).26–29
Although patient-related diagnostic information was not
available to explore the mechanistic links underpinning the
results, a main strength of the study was nationwide coverage
Table 3 Risk of primary skin cancer as a second tumour after a nonskin cancer primary, stratified over family history of skin cancer
Number of first-degree relatives with skin cancer
Trend test
P-value
≥ 1 0
n RR n RR
Primary nonskin, followed by invasive skin cancer
Upper aerodigestive tract 4 768 (288–2047)** 112 569 (484–667)** < 0001
Colorectal 6 352 (158–783)** 141 151 (131–173)** < 0001
Breast 13 447 (259–771)** 277 161 (145–179)** < 0001
Prostate 14 262 (155–442)** 423 151 (139–164)** < 0001
Melanoma 10 660 (355–1227)** 260 381 (341–425)** < 0001
Non-Hodgkin lymphoma 6 962 (432–2142)** 171 523 (458–599)** 013
Leukaemia 8 2049 (1024–4099)** 189 758 (666–864)** < 0001
All (except skin) 78 427 (341–533)** 2100 210 (201–219)** < 0001
Primary nonskin, followed by in situ skin cancer
Upper aerodigestive tract 3 356 (115–1105)* 132 349 (301–405)** 018
Colorectum 8 277 (139–555)** 187 109 (096–124) < 0001
Breast 21 336 (219–516)** 560 144 (133–155)** < 0001
Endometrium 4 289 (109–771)* 109 129 (110–153)** 001
Ovary 3 425 (137–1318)* 44 125 (097–160) 018
Prostate 15 233 (140–387)** 601 148 (137–159)** < 0001
Melanoma 18 659 (415–1046)** 586 490 (456–526)** < 0001
Leukaemia 11 1756 (972–3171)** 175 670 (601–746)** 0001
All (except skin) 106 345 (285–418)** 2993 195 (188–201)** < 0001
RR, Relative risk; CI, confidence interval. *P < 005, **P < 001.
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of cancers from a high-quality cancer registry, which, in con-
trast to most other cancer registries, also collects data on in situ
SCC. In addition, the high confidence in the proper distinction
of tumour types is granted due to histological classification of
tumours. Moreover, for the reporting of SPC, there is a tradi-
tion mandated by requirement for the clinicians to report any
cancers, irrespective of their order.
Our novel findings demonstrated detrimental survival
probabilities for patients with SCC who have a SPC, and fur-
ther showed that family history had no effect on survival. A
three- to fourfold increased HR was both observed for
patients with invasive and in situ SCC with family history,
indicating that SCC of excellent prognosis is, on diagnosis of
SPC, converted to SCC of critical and unpredictable
prognosis. Although family history had no direct effect on
survival for invasive SCCs, it predisposes patients with SCC
to SPCs with approximately a twofold increase in risk, thus
increasing the proportion of patients with SPC. As the SPCs
with a family history included colorectal, lung and breast
cancers as well as melanoma, vigilant monitoring of family
history at SCC diagnosis may prompt recommendations for
prevention (e.g. advice about smoking for lung cancer) or
early detection of SPCs (colorectal and breast cancers and
melanoma), and thus improve survival in patients with SCC.
Finally, our findings suggest that SCC may be a useful ‘ca-
nary in the coal mine’ for highlighting underlying genetic
predisposition to various types of epithelial cancers. Further
work is needed to dissect the contributing mechanisms.
(a)
(b)
Fig 1. Kaplan–Meier survival curves for patients with squamous cell carcinoma (SCC): (a) invasive SCC and (b) in situ SCC, with and without
second primary cancer (SPC), grouped over presence or absence of family history (FH) of any cancer. The shaded area around the curves shows
95% confidence intervals.
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However, families with high numbers of SCC and non-SCC
cancers could prove useful in this regard.
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